Avastin Misses Mark Again in Breast Cancer (CME/CE)

SAN ANTONIO (MedPage Today) -- The addition of bevacizumab (Avastin) to standard adjuvant therapy for HER2-positive breast cancer failed to improve invasive disease-free survival in a randomized clinical trial.

Source: MedPage Today Hematology/Oncology - December 11, 2013 Category: Hematology Source Type: news